<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01948921</url>
  </required_header>
  <id_info>
    <org_study_id>DalinTCGH-hsieh-2013-3</org_study_id>
    <nct_id>NCT01948921</nct_id>
  </id_info>
  <brief_title>Meperidine for Patients Expected to Have Poor Tolerance During Diagnostic Esophagogastroduodenoscopy.</brief_title>
  <official_title>Meperidine as the Single Sedative Agent for Patients Expected to Have Poor Tolerance During Diagnostic Esophagogastroduodenoscopy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dalin Tzu Chi General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dalin Tzu Chi General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our pilot results showed that meperidine reduce patient discomfort during EGD
      (esophagogastroduodenoscopy). But many patients can tolerate EGD well without any sedative
      agents. So the investigators target the use of meperidine on patients expected to have poor
      tolerance in this study, which includ young females with high anxiety level and patients with
      prior poor tolerance. The investigators test the hypothesis that meperidine improves
      tolerance and alleviates discomfort for patients expected to have poor tolerance during
      diagnostic EGD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>discomfort score during esophageal intubation</measure>
    <time_frame>10 minutes</time_frame>
    <description>self-reported discomfort score during esophageal intubation, assessed with a 0 to 10 (0 = none; 10 = unbearable) visual analog scale (VAS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>patient discomfort score during the procedure</measure>
    <time_frame>10 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patients satisfaction score</measure>
    <time_frame>10 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient tolerance score evaluated by the endoscopist</measure>
    <time_frame>10 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endoscopist satisfaction score</measure>
    <time_frame>10 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Patients Undergoing Diagnostic EGD</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 ml normal saline will be given 5 minutes before EGD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meperidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 mg intramuscular meperidine will be given 5 minutes before EGD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meperidine</intervention_name>
    <arm_group_label>meperidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female youger than 65 years with high anxiety level

          -  patients with previous poor tolerance of EGD

        Exclusion Criteria:

          -  a therapeutic EGD

          -  sedation with other agents

          -  contraindication to Buscopan (hyoscine N-butylbromide) or meperidine

          -  American Society of Anesthesiology (ASA) risk Class 3 or higher, renal failure

          -  age less than 20 years or more than 80 years

          -  pregnancy

          -  refusal to provide written informed consent. All participants signed written informed
             consents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Buddhist Dalin Tzu Chi General Hospital</name>
      <address>
        <city>Chia-Yi</city>
        <zip>622</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Abraham NS, Fallone CA, Mayrand S, Huang J, Wieczorek P, Barkun AN. Sedation versus no sedation in the performance of diagnostic upper gastrointestinal endoscopy: a Canadian randomized controlled cost-outcome study. Am J Gastroenterol. 2004 Sep;99(9):1692-9.</citation>
    <PMID>15330904</PMID>
  </reference>
  <reference>
    <citation>Hsieh YH, Lin HJ, Hsieh JJ, Tseng KC, Tseng CW, Hung TH, Leung FW. Meperidine as the single sedative agent during esophagogastroduodenoscopy, a double-blind, randomized, controlled study. J Gastroenterol Hepatol. 2013 Jul;28(7):1167-73. doi: 10.1111/jgh.12183.</citation>
    <PMID>23431993</PMID>
  </reference>
  <reference>
    <citation>Ishido S, Kinoshita Y, Kitajima N, Itoh T, Nishiyama K, Tojo M, Yano T, Inatome T, Fukuzaki H, Chiba T. Fentanyl for sedation during upper gastrointestinal endoscopy. Gastrointest Endosc. 1992 Nov-Dec;38(6):689-92.</citation>
    <PMID>1473671</PMID>
  </reference>
  <reference>
    <citation>Laluna L, Allen ML, Dimarino AJ Jr. The comparison of midazolam and topical lidocaine spray versus the combination of midazolam, meperidine, and topical lidocaine spray to sedate patients for upper endoscopy. Gastrointest Endosc. 2001 Mar;53(3):289-93.</citation>
    <PMID>11231385</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2013</study_first_submitted>
  <study_first_submitted_qc>September 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2013</study_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dalin Tzu Chi General Hospital</investigator_affiliation>
    <investigator_full_name>Yu-Hsi hsieh</investigator_full_name>
    <investigator_title>Chief of Gastroenterology Endoscopy Suite</investigator_title>
  </responsible_party>
  <keyword>EGD</keyword>
  <keyword>tolerance</keyword>
  <keyword>discomfort</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meperidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

